Publications by authors named "Sabrin Moumene"
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease leading to hemolysis, with C5 inhibitors improving treatment but having limited effects on some hemolysis types.
- The newly approved C3 inhibitor, pegcetacoplan, effectively reduces both intravascular and extravascular hemolysis, enhancing hemoglobin levels and quality of life for patients.
- A cost-utility analysis showed pegcetacoplan is less expensive over 5 years (€1,483,454) compared to C5 inhibitors and provides greater increases in quality-adjusted life years (QALYs) while reducing management costs associated with complications.
Background: Cardiovascular diseases pose a significant challenge to the society and healthcare systems, with serious implications in terms of mortality and healthcare expenditure. The treatment of cardiovascular diseases, based on acetylsalicylic acid combined with statins in multi-pill regimens, is characterized by a lower adherence rate among patients compared to the single-pill combination. A potential solution lies in single-pill formulations, drugs that combine two or more active ingredients at a fixed dosage within the same dosage unit.
View Article and Find Full Text PDF